|Bid||0.00 x 800|
|Ask||241.38 x 900|
|Day's range||239.83 - 244.95|
|52-week range||129.21 - 275.87|
|Beta (5Y monthly)||0.31|
|PE ratio (TTM)||36.27|
|Earnings date||26 Oct 2021|
|Forward dividend & yield||3.40 (1.40%)|
|Ex-dividend date||12 Nov 2021|
|1y target est||N/A|
Merck (NYSE: MRK) and its partner, Ridgeback Biotherapeutics, hope to soon win U.S. Emergency Use Authorization (EUA) for the first COVID-19 pill. In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss the potential impact of Merck's pill on COVID-19 antibody therapies.
Teladoc Health (TDOC) is likely to report a strong revenue outperformance for the third quarter, driven by broad-based momentum across its business and a sharp acceleration in visit-volume growth.
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) third-quarter sales.